Adjuvant Capital

VCMatch tracks Adjuvant Capital as an investor focused on Biotech, Medtech, and Pharma companies, Series A and Series B rounds, Low And Middle Income Countries (Lmi Cs), Emerging Economies, and Global markets, and $12m to $300m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$12m to $300m

Stages

Series A, Series B, Series C, Late Stage

Focus Areas

Biotech, Medtech, Pharma

Geography

low- and middle-income countries (LMICs), emerging economies, and global

Investment Thesis

Adjuvant positions itself as a purpose-driven life‑sciences investor that uses venture capital “to improve global health.” The firm focuses capital on technologies addressing high‑burden and neglected public‑health challenges (infectious diseases, maternal & child health, nutrition, reproductive & sexual health) and prioritizes investments that already have human efficacy signals with the explicit goal of accelerating global availability and access. Adjuvant combines an impact mandate (making interventions accessible in low‑ and middle‑income countries) with a commercial orientation aimed at delivering differentiated “double‑bottom‑line” social and financial returns.

Is Adjuvant Capital right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Adjuvant Capital is most relevant for founders raising Series A, Series B, and Series C rounds in Biotech, Medtech, and Pharma, especially across low- and middle-income countries (LMICs), emerging economies, and global, with public check-size signals around $12m to $300m.

Focus statement

Adjuvant invests in innovative vaccines, therapeutics, diagnostics and devices for neglected, high‑burden and emerging public health challenges—particularly infectious diseases (including the “big three,” tropical diseases, pandemic threats and AMR), maternal/newborn/child health, reproductive & sexual health, and nutrition—and directs the majority of activity toward opportunities with phase II‑or‑later human efficacy evidence.

Value Add

Explicit LMIC / global‑health orientation focused on historically overlooked market segments rather than traditional life‑sciences VC markets
Targeting ‘double‑bottom‑line’ returns: pursuit of both top‑tier financial returns and measurable public‑health impact
Evidence‑driven stage focus: majority of investments are preferred equity in technologies with "human efficacy signals from a phase II‑or‑later clinical trial" or similar proof‑of‑concept data
Investment model and sourcing supported by deep ties to the global health community and major funders (site cites backing/relationships with Novartis, Merck, International Finance Corporation, and the Bill & Melinda Gates Foundation)
Cross‑disciplinary team: venture and private equity investors combined with global public‑health leaders, disease technical experts, and pharmaceutical industry veterans to support sourcing and execution
Strategy informed by macro public‑health trends (climate change, women’s empowerment, urbanization, AMR, globalization) to anticipate looming threats and opportunities